Nexstim Plc · OMXHEX:NXTMH
Nexstim — Nordic Life Science Days 2015
12 slides from Nexstim's conference presentation, Sep 10, 2015
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Mikko Karvinen | CFO | Nexstim Nordic Life Science Days 2015, September 10, Stockholm @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj FORWARD-LOOKING STATEMENTS (“Nexstim” or the “Company”). In connection with any presentation or review of this This document may contain forward-looking statements that reflect the Company’s c
Slide 3: Introduction to Nexstim
Introduction to Nexstim Novel medtech company with strong position in brain navigation technology and software Ongoing CE mark & pivotal Phase Significant FDA III study in unmet need clearance for stroke in post acute e-field based rehabilitation stroke navigation rehabilitation Targeted growth in U
Slide 4: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Nexstim’s Nexstim’sNavigated NavigatedBrain BrainTherapy® Therapy®solution (NBT) Targeting Targetingaablockbuster blockbustermarket… market for stroke solution rehabilitation for stroke rehabilitation (market for post-acute stroke treatment) 2.1 mi
Slide 5: Positioned within Stroke Care Path
Positioned within Stroke Care Path Days 0-10 Days 10-90 3-12 months from stroke 12 months onwards Acute Stabilisation and Post-acute rehab, Broken care path care spontaneous recovery chronic patients NBT® Acute care to Early rehab and normal healing Currently, patients are discharged from Annual reh
Slide 6: NBT for stroke rehabilitation – How it works
NBT® for stroke rehabilitation – How it works Validated e-Field Navigation gives Competitive Edge Using a patient’s own MRI scan as a guide, Nexstim Because the injured side is no longer dominated by provides precisely targeted, personalized, the healthy side of the brain, it is more responsive magn
Slide 7: Efficacy demonstrated in Phase II trial
Efficacy demonstrated in Phase II trial Change in upper extremity Fugl-Meyer score from baseline Trial outcome: Absolute average improvement of 20 13.8 Fugl-Meyer scores 15 P<0.05 = difference of "holding an object" and "buttoning a shirt" 84% responder rate (above "MCID" for NBT® group) Difference:
Slide 8: Phase III trials - Laying the groundwork for commercialisation
Phase III trials - Laying the groundwork for commercialisation Study in brief Study goals Conducted at 12 top US rehab sites ● Establish clinical efficacy ● Document Rehabilitation Institute of Chicago (central site) of NBT® in upper-limb effects/efficacy of TIRR Memorial Hermann Hospital (Houston)
Slide 9: Status of Clinical Development
Status of Clinical Development Progressing as Planned ● The clinical Phase III multi-center trial is progressing and enrolling patients according to plans. The next interim analysis milestones are estimated to be reached Q3 2015 and Q1 2016 and the clinical evidence is assumed to be ready by the end
Slide 10: Financials
Financials EUR in thousands H1 2015 H1 2014 FY 2014 6 months 6 months 12 months Revenue growth from device sales Net sales 643.2 413.9 2,210.4 with CAPEX Profit/ -Loss for the period -4,555.0 -5,127.3 -10,445.4 business model Cash flows from operating activities -5,275.3 -2,508.1 -7,785.2 IPO improv
Slide 11: Summary and Future Outlook
Summary and Future Outlook Targeting a Paradigm Shift in Stroke Rehabilitation ● World-leading medical technology and software with game changing potential in stroke rehabilitation ● Good progress since IPO ● NBT® Phase III study proceeding well with interim data due in Q3 2015 and Q1 2016 ● Based o
Slide 12: Thank you
Targeting a paradigm shift in stroke rehabilitation Thank you @NexstimOyj